Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) to a hold rating in a report released on Saturday.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC stock opened at $3.31 on Friday. The firm has a market cap of $5.25 million, a P/E ratio of 0.00 and a beta of 0.03. Cyclacel Pharmaceuticals has a 1-year low of $3.08 and a 1-year high of $597.60. The firm has a fifty day moving average of $20.07 and a two-hundred day moving average of $56.08.

Cyclacel Pharmaceuticals Announces Dividend

The firm also recently declared a dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 29th were issued a $36.00 dividend. The ex-dividend date of this dividend was Tuesday, April 29th. Cyclacel Pharmaceuticals’s dividend payout ratio (DPR) is presently -0.02%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC increased its holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 118.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,269,485 shares of the biotechnology company’s stock after buying an additional 689,024 shares during the period. Armistice Capital LLC owned about 0.61% of Cyclacel Pharmaceuticals worth $354,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.